Is MEDXF or NOBL a better dividend investment in 2026?

MEDXF currently yields 89.29% with a 5% 5-year dividend growth rate. NOBL yields 2.14% with 5% growth. The better choice depends on your goal: MEDXF offers higher current income.

What is the dividend yield difference between MEDXF and NOBL?

MEDXF has a forward dividend yield of 89.29% ($2.00/share annually). NOBL yields 2.14% ($2.27/share annually). The yield gap is 87.15 percentage points.

Home › Compare › MEDXF vs NOBL

MEDXF vs NOBL: Dividend Comparison 2026

MEDXF yields 89.29% · NOBL yields 2.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MEDXF wins by $2.47M in total portfolio value

INVESTMENT

TIME HORIZON10 years

MEDXF

● Live price

89.29%

Share price

$2.24

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2.49M

Annual income

$776,963.67

Full MEDXF calculator →

NOBL

● Live price

2.14%

Share price

$106.01

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.8K

Annual income

$246.19

Full NOBL calculator →

Portfolio growth — MEDXF vs NOBL

📍 MEDXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MEDXF	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MEDXF + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MEDXF pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MEDXF

Annual income on $10K today (after 15% tax)

$7,589.29/yr

After 10yr DRIP, annual income (after tax)

$660,419.12/yr

NOBL

Annual income on $10K today (after 15% tax)

$182.19/yr

After 10yr DRIP, annual income (after tax)

$209.26/yr

At 15% tax rate, MEDXF beats the other by $660,209.86/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MEDXF + NOBL for your $10,000?

MEDXF: 50%NOBL: 50%

100% NOBL50/50100% MEDXF

Portfolio after 10yr

$1.26M

Annual income

$388,604.92/yr

Blended yield

30.94%

📊

Analyst Conviction Gap

Where Wall Street is split right now

MEDXF

Analyst Ratings

Hold

Consensus: Hold

Altman Z

0.9

Piotroski

5/9

NOBL

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MEDXF buys

NOBL buys

No recent congressional trades found for MEDXF or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMEDXFNOBL

Forward yield	89.29% ✓	2.14%
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$2.49M	$22.8K ✓
Annual income after 10y	$776,963.67 ✓	$246.19
Total dividends collected	$2.19M	$2.3K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: MEDXF vs NOBL ($10,000, DRIP)

Year	MEDXF Portfolio	MEDXF Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$19,629	$8,928.57	$10,914	$214.34	+$8.7K → MEDXF
2	$37,382	$16,378.98	$11,897	$218.63	+$25.5K → MEDXF
3	$69,150	$29,152.23	$12,952	$222.72	+$56.2K → MEDXF
4	$124,390	$50,399.46	$14,086	$226.62	+$110.3K → MEDXF
5	$217,827	$84,729.38	$15,302	$230.33	+$202.5K → MEDXF
6	$371,743	$138,667.67	$16,607	$233.85	+$355.1K → MEDXF
7	$618,933	$221,167.77	$18,007	$237.18	+$600.9K → MEDXF
8	$1,006,401	$344,142.93	$19,508	$240.35	+$986.9K → MEDXF
9	$1,599,826	$522,977.14	$21,116	$243.35	+$1.58M → MEDXF
10	$2,488,777	$776,963.67	$22,841	$246.19	+$2.47M → MEDXF

MEDXF vs NOBL: Complete Analysis 2026

MEDXF — Stock

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Full MEDXF Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this MEDXF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MEDXF vs SCHD MEDXF vs JEPI MEDXF vs O MEDXF vs KO MEDXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.